唑来膦酸联合化疗治疗多发性骨髓瘤骨病的疗效分析  

The therapeutic effect of zoledronic acid combined with chemotherapy in the treatment of myeloma bone disease

作　　者：李春霞 刘蕴华 

机构地区：[1]信阳市中心医院血液内科,河南信阳464000

出　　处：《现代肿瘤医学》2014年第7期1673-1675,共3页Journal of Modern Oncology

摘　　要：目的:探讨唑来膦酸联合化疗治疗多发性骨髓瘤骨病的疗效及安全性。方法:50例多发性骨髓瘤患者,按治疗方案的不同随机分为联合组24例,即唑来膦酸联合VAD方案治疗组;化疗组26例,单用VAD方案化疗组。观察两组骨痛缓解的总有效率及不良反应发生率。结果:联合组与化疗组的骨痛缓解的总有效率分别为95.8%(23/24)与73.1%(19/26),差异有统计学意义(P<0.05)。联合组10例患者影像学检查显示骨质破坏范围有所缩小或新骨形成;化疗组影像学检查示骨质病变有不同程度进展。两组不良反应发生率分别为25%(6/24)与26.9%(7/26),差异无统计学意义(P>0.05)。结论:唑来膦酸联合化疗治疗多发性骨髓瘤骨病的疗效确切,不良反应发生率少,患者可耐受。Objective：To discuss the therapeutic effect and safety of zoledronic acid combined with chemotherapy in the treatment of myeloma bone disease. Methods：All 50 patients were observed, 24 were treated with zoledronic acid combined with chemotherapy （combination group） and 26 were treated with VAD regimen （chemotherapy group）. Results ：There was significant difference in the rate of bone remission rate between the combined group （95.8% ,23/24） and the VAD group（73.1%, 19/26）（P 〈 0.05）. The scope of bone destruction was reduced or new bone was foemed among 10 patients of combination group though image diagnose. While bone destruction of the chemotherapy group was accentateded in some degree though image diagnose. There were no significant differences in side effect rates between the combination group （25% ,6/24） and the VAD group （26.9% ,7/26） （P 〉0.05）. Con- clusion：The combination of zoledronic acid and VAD regimen is an efficient, safe and endurable regimen for myeloma bone disease.

关 键 词：骨髓瘤骨病 唑来膦酸 VAD方案 骨痛 

分 类 号：R733.3[医药卫生—肿瘤]